Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Protease inhibitors in development at SmithKline Beecham

April 30, 1999

Amylin's pramlintide given trademark

April 30, 1999

Purified flaxseed lignan has significant beneficial effects in hypercholesterolemic atherosclerosis

April 29, 1999

New cyclic compounds designed at JT reduce only elevated blood glucose levels

April 27, 1999

New phenylpropionic acid derivatives with excellent antidiabetic effects

April 27, 1999

FDA approves Roche's lipase inhibitor for marketing

April 27, 1999

SmithKline Beecham enters copromotion agreement with Bristol-Myers Squibb for Avandia

April 26, 1999

HMR seeks approval for long-acting insulin in U.S. and Europe

April 26, 1999

SS Pharm. presents new AGE inhibitors for use in diabetic complications

April 26, 1999

Pharmacokinetics of Prandin shown to be similar in young adults and elderly

April 26, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...